DEA Awards Licenses for Cannabis Production and Medical Research to Royal Emerald Pharmaceuticals
Royal Emerald Pharmaceuticals, a leading cannabis pharmaceutical company, announced it has received four licenses from the DEA to grow, research, develop, and manufacture alternative drugs derived from cannabis and other botanicals.
On January 18th, Royal Emerald Pharmaceuticals (REP), a leading cannabis pharmaceutical company, announced it has received four licenses from the US Drug Enforcement Administration (DEA) to grow, research, develop, and manufacture alternative drugs derived from cannabis and other botanicals in December 2021.According to the announcement, REP is the first-of-its-kind cannabis pharmaceutical company in the US to receive these federal licenses. Considering how cannabis is currently classified by the DEA as a Schedule I drug, this move is a historic win for the cannabis industry and signals the federal government loosening its grip on important, cannabis-related medical research.
Established in 2017 and located in Desert Hot Springs, California, REP’s mission is to create alternative drugs designed specifically for veterans, law enforcement, and first responders who suffer from chronic pain, opioid addiction, post-traumatic stress disorder (PTSD), anxiety, depression, sleep apnea, and other life-threatening ailments.REP will supply state-of-the-art drugs and active pharmaceutical ingredients derived from tetrahydrocannabinol (THC) and cannabidiol (CBD) to DEA registrants, researchers, universities, colleges, and government agencies, including the Veterans Administration (VA), and the international medical market.
“We are excited and very happy to receive these DEA licenses for cannabis research,” said Mark Crozier, Founder and CEO of Royal Emerald Pharmaceuticals. “This news is huge and comes with immense responsibilities—we have been chosen to provide researchers and universities with high quality cannabis so they can move forward with their research projects. These researchers have struggled for decades to be recognized by the medical and scientific communities. Now, they can.”
Plant growth metrics and data will be monitored and collected by REP’s partner, RapidGrow LED Technologies, Inc., a vertically integrated manufacturing and light-emitting diode (LED) lighting technology company. RapidGrow has an open architecture and fully wireless technology platform, which will gather data and generate real-time reporting of key growth variables—such as temperature, humidity, photosynthetically active radiation (PAR), CO2, soil moisture content, heating, ventilation, and air conditioning (HVAC), PH, vapor pressure deficit, and more—to ensure quality, consistency, and repeatability for REP and the DEA.
“RapidGrow is proud to partner with REP on such an historic and significant mission to support medical research projects with the most advanced indoor grow lighting technology,” said Bryan Fried, President and CEO of RapidGrow.
For more information on Royal Emerald Pharmaceuticals please visit https://www.royalemeraldrx.com/.
For more information on RapidGrow LED Technologies, Inc., please visit https://rapidgrowled.com/.
Reference
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
